LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・Beam Therapeutics Inc

Beam Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.89 4.11

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.24

Max

27.9

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -113M
Pardavimai	1.2M 9.7M
Pelno marža	-1,162.384
Darbuotojai	510
EBITDA	-10M -107M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+86.84% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	315M 2.8B
Ankstesnė atidarymo kaina	23.78
Ankstesnė uždarymo kaina	27.89

Naujienos nuotaikos

By Acuity

22%

78%

48 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

16.225 / 20.17 Palaikymas ir pasipriešinimas

Beam Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-13 16:32; UTC

Uždarbis

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026-02-13 21:57; UTC

Uždarbis

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026-02-13 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:20; UTC

Uždarbis

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026-02-13 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026-02-13 20:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-13 20:45; UTC

Rinkos pokalbiai

Dollar Pares Down Early Losses -- Market Talk

2026-02-13 20:39; UTC

Rinkos pokalbiai

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026-02-13 20:28; UTC

Rinkos pokalbiai

Oil Settles Week Lower -- Market Talk

2026-02-13 19:51; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:29; UTC

Uždarbis

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026-02-13 18:18; UTC

Įsigijimai, susijungimai, perėmimai

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026-02-13 17:52; UTC

Uždarbis

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026-02-13 17:16; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026-02-13 16:59; UTC

Uždarbis

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026-02-13 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026-02-13 16:11; UTC

Uždarbis

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026-02-13 16:07; UTC

Rinkos pokalbiai

Hungarian Forint Could Rise Further -- Market Talk

2026-02-13 15:54; UTC

Uždarbis

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026-02-13 15:26; UTC

Rinkos pokalbiai

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026-02-13 15:01; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026-02-13 15:00; UTC

Uždarbis

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026-02-13 14:50; UTC

Rinkos pokalbiai

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026-02-13 14:44; UTC

Uždarbis

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026-02-13 14:22; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-13 14:21; UTC

Rinkos pokalbiai

Uždarbis

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026-02-13 14:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Move Lower -- Market Talk

Akcijų palyginimas

Kainos pokytis

Beam Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

86.84% į viršų

12 mėnesių prognozė

Vidutinis 48.56 USD 86.84%

Aukščiausias 80 USD

Žemiausias 28 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Beam Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Beam Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

16.225 / 20.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

48 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.